Nov 13, 2023

Between them, AdAPT-001 and RRx-001/nibrozetone are potentially active against a range of “-itises,” literally meaning inflammatory diseases. These may include encephalitis, hypophysitis, carditis, pneumonitis, stomatitis, gingivostomatitis, parotitis, esophagitis, colitis, arthritis, and pneumonitis among others.

The mechanisms behind this broad-spectrum activity involve, on the one hand, NLRP3 inflammasome inhibition and Nrf2 activation by RRx-001/nibrozetone and, on the other hand, transforming growth factor-beta (TGF-β) antagonism by AdAPT-001.

To date, however, the one “-itis” against which AdAPT-001 and RRx-001/nibrozetone have not been tested is, Mondayitis. This cyclical syndrome manifests every 6 days in humans only, as far as we know, with several hallmark signs and symptoms including irritability, fatigue, brain fog, poor attention span, disheveled appearance, frequent grunting, lack of eye contact and an overwhelming desire to play hooky from work or school.

Like long COVID or chronic fatigue syndrome (CFS), the exact pathophysiology behind Mondayitis, is unknown. Several leading theories, none of which are mutually exclusive, include 1) Hangover-like effects from too much alcohol and/or too many potato chips over the weekend. 2) Disruption to the normal circadian rhythm from staying up late to party or to binge favorite shows on Netflix. 3) Caffeine withdrawal due to early morning meetings that prevent waiting on long lines at Starbucks for the unrushed baristas to, we suspect, intentionally mispronounce your name. 4) Transient inflammation from a viral infection acquired the week before and/or from “cocktail flu” (see number 1.) 5) Genetic variation.

Although Mondayitis is not necessarily a life-threatening disorder, it is a chronic, urgent, unmet medical need that we at EpicentRx have resolved to treat.

Starting on Tuesday.